Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated claim is directly and unambiguously supported by the provided FDA label boxed warning and Warnings and Precautions section 5.1, with no contradictions or relevant omissions for the limited scope of the claim.
Category Scores
Accurate Statements
Premature discontinuation of ELIQUIS increases the risk of thrombotic events.
Boxed Warning (A): “Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events.”; Warnings and Precautions (5.1): “Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The evaluated statement concerns a labeled boxed warning about thrombotic risk after premature discontinuation and is accurately reflected; no additional patient-specific safety instructions were claimed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
No issues identified for the evaluated claim.
Suggested Improvement
If expanding beyond this single claim, ensure all additional statements are checked against the corresponding label sections (e.g., specific switching, peri-procedural interruption timelines, neuraxial hematoma precautions).